pSivida Corp. (Nasdaq: PSDV) reported positive results from its second Phase 3 trial of Durasert three year treatment for posterior segment uveitis but the stock price fell 33 cents to close at $1.75.
pSividia reports upbeat results
June 13, 2017 at 17:31 PM EDT
